Hyperbaric Oxygen Therapy and Acute Kidney Injury
Hyperbaric Oxygen Therapy for Cardiac Surgery-Associated Acute Kidney Injury: A First-in-Human Pilot Study
1 other identifier
interventional
7
1 country
1
Brief Summary
Kidney injury is a serious complication of cardiac surgery that occurs in up to 30% of patients and increases the risk of adverse outcomes. Kidney injury initiates when oxygen supply to the kidney drops below levels that are needed for normal cellular function, causing tissue oxygen deficiency (hypoxia), activation of the inflammatory cascade, and oxidative stress. Together, these events further impair tissue oxygenation, culminating in impaired kidney function due to cellular injury and death. There are no effective therapies for kidney injury after cardiac surgery, but there is evidence that recovery is possible if the processes of injury - i.e., impaired oxygen delivery, increased inflammatory response, and oxidative stress - are ameliorated soon after the onset of injury. Hyperbaric oxygen therapy (HBOT) - which entails the intermittent inhalation of 100% oxygen in a hyperbaric chamber at a pressure higher than one absolute atmosphere (\> 760 mmHg) - has been shown to positively affect all of these processes (i.e., to improve tissue oxygenation, reduce inflammation, and reduce oxidative stress). Thus, we hypothesized that HBOT will reduce the severity of kidney injury after cardiac surgery if it is initiated soon after onset of injury. This hypothesis has not been tested in humans, but is supported by animal studies. In this first-in-human, unblinded, controlled pilot trial, 20 adult patients who develop severe kidney injury soon after cardiac surgery will be randomized (after obtaining informed consent from the patient or surrogate) to standard-of-care or early HBOT. Severe kidney injury will be defined as a ≥30% drop in kidney function within 6 hours of surgery (as determined by change in creatinine from before surgery to Intensive Care Unit (ICU) admission). This degree of injury occurs in \~ 2% of patients and is associated with a 12-fold increase in the risk of complete kidney failure (requiring dialysis) or death. Patients will be excluded if they have any relative or absolute contraindications to HBOT (e.g., severe ventricular dysfunction, ventricular assist device, severe respiratory dysfunction, pneumothorax, bronchospasm).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2016
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 30, 2015
CompletedFirst Posted
Study publicly available on registry
April 19, 2016
CompletedStudy Start
First participant enrolled
June 10, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 7, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2019
CompletedMay 17, 2019
May 1, 2019
1.2 years
November 30, 2015
May 15, 2019
Conditions
Outcome Measures
Primary Outcomes (2)
Feasibility of the intervention
The proportion of patients qualified but not consented and the proportion of patients completing the study from each group.
7 days
Safety of the intervention as assessed by adverse events
Adverse events that are related to the intervention.
7 days
Study Arms (2)
Standard Therapy
PLACEBO COMPARATORStandard supportive therapies for Acute Kidney Injury (AKI), which entail optimization of hemodynamics and hemoglobin levels.
Standard Therapy and hyperbaric oxygen
ACTIVE COMPARATORStandard therapies and treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 atmospheres absolute (ATA).
Interventions
The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
Eligibility Criteria
You may qualify if:
- age \> 18 years
- any cardiac surgery with cardiopulmonary bypass surgery
- ≥30% drop in kidney function within 6 hours of surgery (determined by change in creatinine from before surgery to ICU admission)
You may not qualify if:
- Pre-existing renal dysfunction (creatinine \> 177 µmol/L)
- claustrophobia
- seizure disorder
- severe respiratory dysfunction (PaO2/fraction of inspired oxygen (FiO2) ratio \<150 on 100% O2 and Peep of 10)
- active asthma or bronchospasm
- severe chronic obstructive pulmonary disease
- history of spontaneous pneumothorax or untreated pneumothorax
- congestive heart failure with left ventricular ejection fraction \< 30%
- evidence of ongoing myocardial ischemia
- presence of ventricular assist device or intra-aortic balloon pump
- chronic sinusitis
- chronic/ acute otitis media or major ear drum trauma
- current treatment with bleomycin, cisplatin, doxorubicin and disulfiram
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Toronto General Hopsital University Health Network
Toronto, Ontario, M5G 2C4, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Keyvan Karkouti, MD
University Health Network, Toronto
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 30, 2015
First Posted
April 19, 2016
Study Start
June 10, 2016
Primary Completion
September 7, 2017
Study Completion
May 1, 2019
Last Updated
May 17, 2019
Record last verified: 2019-05